A genome-wide CRISPR-Cas9 screen identifies Rab5A as potential hepatitis E drug target

Utilising a genome-wide CRISPR-Cas9 screen in human cells with hepatitis E virus (HEV) subgenomic replicons, researchers at University of Lausanne, Switzerland, identified the Ras-related protein Rab5A as crucial for HEV RNA replication.

By: Gorm Palmgren - Dec. 19, 2023
News

#CRISPRMED24

Targeted silencing of Rab5A and related endosomal proteins notably reduced HEV RNA replication, while late endosome components had no effect. Pharmacological inhibition of Rab5A also decreased replication in a dose-dependent manner.

Co-localisation studies suggest Rab5A and early endosomes as scaffolds for HEV replication complexes, shedding light on HEV lifecycle and host interactions essential for infection.

The study was published yesterday in PNAS: https://doi.org/10.1073/pnas.2307423120

To get more of the CRISPR Medicine News delivered to your inbox, sign up to the free weekly CMN Newsletter here.

Tags

HashtagArticleHashtagCMN BriefsHashtagMissing linksHashtagNewsHashtagCRISPR Therapeutics AG

News: A genome-wide CRISPR-Cas9 screen identifies Rab5A as potential hepatitis E drug target
News: A genome-wide CRISPR-Cas9 screen identifies Rab5A as potential hepatitis E drug target
CLINICAL TRIALS
Renal Cell Carcinoma, RCC, (NCT06245915)
Sponsors:
Arsenal Biosciences, Inc.
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Solid Tumors, (NCT06237881)
Sponsors:
M.D. Anderson Cancer Center
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Breast Cancer, BC, (NCT05812326)
Sponsors:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine